The
European Partnership for Personalised Medicine:
Goals
The European Partnership for Personalised
Medicine, EP PerMed, will be one
of the European Partnerships under the European
Union’s 9th Framework Programme for Research and
Innovation, Horizon Europe. So far, 49 European
Partnerships are foreseen in total and nine of
these are in the Cluster “Health”.
The general aim of the European Partnerships is
to bring the European Commission and private
and/or public partners together to address some of
Europe’s most pressing challenges through
concerted research and innovation initiatives.
EP PerMed will be dedicated to accelerating the
development of personalised medicine in the EU and
Associated Countries.
The European Commission and the Member States
have made large investments in personalised
medicine over the years and this partnership
builds on many of these investments. The creation
of EP PerMed represents a unique strategic
opportunity to bring together stakeholders, create
synergies, coordinate R&I actions and leverage
the efforts to accelerate the evolution of
healthcare towards personalised medicine.
The core of the partnership is to invest in
multidisciplinary, transnational research (basic,
clinical, and translational) and innovation
activities that will build and disseminate new
knowledge, develop new technologies and methods,
as well as supporting testing and piloting of the
implementation of PM approaches. The partnership
will work in close collaboration with other health
partnerships and reach out to national, regional,
and international initiatives and frameworks to
ensure synergies and investments of scale. In
addition, the partnership will include supportive
activities contributing to policy, regulatory
science and strengthening the field of health
economics.
The investments from both Member States and the
Commission for the 7-10 years duration of the
partnership are expected to be over 300 Mio.
Euros.
Further and continually updated information
about the European Partnerships is available on
the websites of the European
Commission and ERA-LEARN. |